Head to Head Survey: Trevi Therapeutics (NASDAQ:TRVI) versus IDEAYA Biosciences (NASDAQ:IDYA)

Trevi Therapeutics (NASDAQ:TRVI) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for Trevi Therapeutics and IDEAYA Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1	0	9	2	3.00
IDEAYA Biosciences	1	1	15	0	2.82

Trevi Therapeutics currently has a consensus price target of $22.90, suggesting a potential upside of 48.70%. IDEAYA Biosciences has a consensus price target of $50.69, suggesting a potential upside of 65.81%. Given IDEAYA Biosciences’ higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Trevi Therapeutics.

Risk & Volatility

Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500.

Profitability

This table compares Trevi Therapeutics and IDEAYA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Valuation and Earnings

This table compares Trevi Therapeutics and IDEAYA Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76 million	($0.32)	-48.13
IDEAYA Biosciences	$218.71 million	12.28	-$113.70 million	($1.60)	-19.11

Trevi Therapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. Trevi Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

IDEAYA Biosciences beats Trevi Therapeutics on 7 of the 13 factors compared between the two stocks.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.